These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8849914)

  • 1. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    Indian J Lepr; 1995; 67(4):375-82. PubMed ID: 8849914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
    Dhople AM
    Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal action at low doses of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on Mycobacterium leprae inoculated into footpads of nude mice.
    Gidoh M; Tsutsumi S; Yamane T; Yamashita K; Hosoe K; Hidaka T
    Lepr Rev; 1992 Dec; 63(4):319-28. PubMed ID: 1479871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648.
    Tomioka H; Saito H
    Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):255-8. PubMed ID: 8371034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activity of rifabutin against Mycobacterium leprae.
    Yoder LJ; Jacobson RR; Hastings RC
    Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic nude mice.
    Maw WW; Tomioka H; Sato K; Saito H
    Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):345-51. PubMed ID: 9401487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice.
    Saito H; Tomioka H; Sato K; Dekio S
    Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):43-7. PubMed ID: 8189088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
    Dhople AM
    Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
    Ji BH; Chen JK; Lu XZ; Wang SY; Ni GX; Hou YH; Zhou DH; Tang QK
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the multiplication of Mycobacterium leprae in nude mice by intermittent administration of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) combined with sparfloxacin.
    Gidoh M; Matsuki G; Tsutsumi S; Hidaka T; Nakamura S
    Lepr Rev; 1995 Mar; 66(1):39-47. PubMed ID: 7731340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
    Dhople AM; Namba K
    Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads.
    Dhople AM; Ortega I; Seydel JK; Gardner GD
    Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
    Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
    Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA; Gardner GD
    Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648.
    Dhople AM
    Arzneimittelforschung; 2001; 51(6):501-5. PubMed ID: 11455683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
    Dhople AM; Namba K
    J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.